The >Your< Back Pain Capsules, combined with physical therapy, provided more pain relief and mobility than physical therapy alone.
In a September 18, 2024, press release, PharmaLinea, (Ljubljana, Slovenia), announced the results of a clinical trial testing the effectiveness of its >Your< Back Pain Capsules in reducing back pain when added the physical therapy. Back pain, explained the press release, affects up to 80% of people at some points in their lifetime. The >Your< Back Pain Capsules were created from PharmaLinea’s proprietary complex, Qspine—which consists of nucleotide complex and vitamins B1, B6, B12, and D3—to target neuronal damage. The prospective, double-blind, randomized study, “Quality of Life in Patients with Lumbosacral Radicular Syndrome and Complete Rehabilitation Program (PRISUM PHSD/1/2022),” was published in April 2024 in Family Medicine and Primary Care: Open Access.
For the trial, which lasted three months, 247 participants were split into two groups, one group treated with physical rehabilitation with the addition of >Your< Back Capsules daily, and the other group treated with physical rehabilitation and a placebo. According to the press release, compared to the 92 patients in the control group, the 151 patients in the test group experienced overall:
Additionally, the >Your< Back Pain Capsules did not cause adverse effects and did not have a risk of addiction, unlike analgesics, a common treatment for back pain.
“Low back pain is the leading cause of disability worldwide,” stated stated Maja Orešnik, Science and Research Director at PharmaLinea, in the press release. “The affected typically seek analgesic drugs to alleviate their symptoms. But for neuropathic pain, which is very common in low back pain, analgesics are often unable to provide the side effects-free, effective relief that consumers seek. This is the goal we aimed to support with our product and the presented clinical study. We are very impressed with the robustness of the results and the product’s efficacy. The results stand out due to the high values of the shown differences, such as 51% higher improvement. These differences were statistically significant across a number of different questionnaires and tests, such as the VAS scale, SF-MPQ, Schober test, and so forth. Importantly, the product was compared against physical therapy and not just placebo capsules, which makes effects more difficult to show, and results even more solid.”
Results from the clinical trial will be presented in an October 2 webinar from PharmaLinea with speakers Maja Orešnik and Dr. Rodica Traistaru, Doctor of Medicine at UMF Craiova, Discipline of Physical and Rehabilitation Medicine.
Last month, PharmaLinea also introduced a new, clinically studied joint support product, as well as line extensions to its >Your< Prediabetiq and >Your< Iron product lines.
References
Kyowa Hakko USA to share new research on its Cognizin citicoline ingredient at SupplySide West 2024
Published: October 15th 2024 | Updated: October 15th 2024According to the company, the new research demonstrates the ingredient’s neuroprotective qualities and potential to enhance cognitive function, and support healthy brain aging.
The Nutritional Outlook Podcast Episode 34: Demystifying Prebiotics and Postbiotics
September 30th 2024In this episode of the Nutritional Outlook Podcast we are looking back on a webcast Nutritional Outlook hosted in May, called “Demystifying the Prebiotic and Postbiotic Markets.” During that event, Sandra Saville, director of education and communication for the International Probiotics Association and Dr. Jessica A. Younes, scientific director of the International Probiotics Association debunked myths about prebiotic and postbiotics, and defined the respective categories to help manufacturers better understand how to responsibly formulate and market prebiotic and postbiotic products.
Balchem’s Newest Launch Optifolin⁺® Brings Innovation to the Folate Market
September 19th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin⁺, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.